Clinical trial
To Examine The Effects Of Lapatinib On Orally And Intravenously Administered…
NCT00258050 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00258050 |
|---|---|
| Title | To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients |
| Official title | A Four-Way Cross-Over Study to Examine the Effects of Lapatinib on the Pharmacokinetics of Orally and Intravenously Administered Midazolam in Cancer Patients |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Neoplasms, Breast |
| Intervention type | Drug |
| Interventions | Midazolam, Lapatinib |
| Enrollment | 24 |
| Start date | Nov 21, 2005 |
| Primary completion | Feb 8, 2007 |
| Completion | Feb 8, 2007 |
| First posted | Nov 24, 2005 |
| Last update posted | Dec 6, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: